In accordance with the guidelines stipulated for the appointment of the nomination committee at IRLAB Therapeutics AB, as decided during the annual general meeting on June 20, 2023, the committee is to be comprised of the Chair of the Board and representatives from the three largest shareholders or shareholder groups registered by Euroclear Sweden AB as of August 31, 2023.
The representatives for the nomination committee for the AGM in 2024 have been designated by the three largest shareholders or groups, and the committee now consists of the following members:
Nomination Committee
Clas Sonesson, Chief Scientific Officer (CSO) at IRLAB and one of the company’s founders. Appointed by a shareholder group, including the company’s founders, representing approximately 14% of shares and votes.
Daniel Johnsson, entrepreneur, business developer, investor, and board member of IRLAB. Appointed by a shareholder group, including the company’s founders, representing about 13% of shares and votes.
Anders Vedin, with a background in executive positions at global pharmaceutical companies and former Chair of the Board of IRLAB. Appointed by a shareholder group representing approximately 13% of shares and votes.
Carola Lemne, Chair of the Board of IRLAB Therapeutics AB.
Together, these committee members have been appointed by owners in IRLAB Therapeutics AB, representing a total of about 40% of the company’s shares and votes as of August 31, 2023.
Further details regarding the nomination committee’s activities and its mandate can be found on the company’s website under the Corporate Governance section. The committee’s proposal will be presented in the notice for the annual general meeting in 2024, available on the company’s website www.irlab.se. The AGM is scheduled for May 22, 2024.
